Primary results of the phase III KEYNOTE-412 study: Pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)

J-P. Machiels; Y. Tao; B. Burtness; M. Tahara; D. Rischin; G. V. Alves; I. P. F. Lima; B. G. M. Hughes; Y. Pointreau; S. Aksoy; S. Laban; R. Greil; M. Burian; M. Hetnal; L. F. Licitra; R. Swaby; Y. Zhang; B. Gumuscu; B. Bidadi; L. L. Siu

doi:10.1016/j.annonc.2022.08.029

Primary results of the phase III KEYNOTE-412 study: Pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)

J-P. Machiels
, Y. Tao
, B. Burtness
, M. Tahara
, D. Rischin
, G. V. Alves
, I. P. F. Lima
, B. G. M. Hughes
, Y. Pointreau
, S. Aksoy
, S. Laban
, R. Greil
, M. Burian
, M. Hetnal
, L. F. Licitra
, R. Swaby
, Y. Zhang
, B. Gumuscu
, B. Bidadi
, L. L. Siu

Dep Oncol
UNICANCER
Yale University
National Cancer Center Japan
Peter Maccallum Cancer Center
Hemato Oncol Div
Pesquisa Clin
Royal Brisbane and Women's Hospital
Inst Oncol
Nose & Throat Med
Paracelsus Private Medical University
Dept Internal Med & Med Specialtie
Andrzej Frycz Modrzewski Krakow University
Fondazione IRCCS Istituto Nazionale Tumori Milan
Merck & Company
University of Toronto

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	S1399-S1399
Number of pages	1
Journal	Annals of Oncology
Volume	33
Issue number	7
Early online date	Sept 2022
DOIs	https://doi.org/10.1016/j.annonc.2022.08.029
Publication status	Published - Sept 2022
Event	Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) - Duration: 9 Sept 2022 → 13 Sept 2022

Access to Document

10.1016/j.annonc.2022.08.029

Cite this

Machiels, J.-P., Tao, Y., Burtness, B., Tahara, M., Rischin, D., Alves, G. V., Lima, I. P. F., Hughes, B. G. M., Pointreau, Y., Aksoy, S., Laban, S., Greil, R., Burian, M., Hetnal, M., Licitra, L. F., Swaby, R., Zhang, Y., Gumuscu, B., Bidadi, B., & Siu, L. L. (2022). Primary results of the phase III KEYNOTE-412 study: Pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC). Annals of Oncology, 33(7), S1399-S1399. https://doi.org/10.1016/j.annonc.2022.08.029

@article{9f500d1823354e1293a7fdbc08419933,

title = "Primary results of the phase III KEYNOTE-412 study: Pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)",

author = "J-P. Machiels and Y. Tao and B. Burtness and M. Tahara and D. Rischin and Alves, \{G. V.\} and Lima, \{I. P. F.\} and Hughes, \{B. G. M.\} and Y. Pointreau and S. Aksoy and S. Laban and R. Greil and M. Burian and M. Hetnal and Licitra, \{L. F.\} and R. Swaby and Y. Zhang and B. Gumuscu and B. Bidadi and Siu, \{L. L.\}",

year = "2022",

month = sep,

doi = "10.1016/j.annonc.2022.08.029",

language = "English",

volume = "33",

pages = "S1399--S1399",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd",

number = "7",

note = "Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) ; Conference date: 09-09-2022 Through 13-09-2022",

}

Machiels, J-P, Tao, Y, Burtness, B, Tahara, M, Rischin, D, Alves, GV, Lima, IPF, Hughes, BGM, Pointreau, Y, Aksoy, S, Laban, S, Greil, R, Burian, M, Hetnal, M, Licitra, LF, Swaby, R, Zhang, Y, Gumuscu, B, Bidadi, B & Siu, LL 2022, 'Primary results of the phase III KEYNOTE-412 study: Pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)', Annals of Oncology, vol. 33, no. 7, pp. S1399-S1399. https://doi.org/10.1016/j.annonc.2022.08.029

Primary results of the phase III KEYNOTE-412 study: Pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC). / Machiels, J-P.; Tao, Y.; Burtness, B. et al.
In: Annals of Oncology, Vol. 33, No. 7, 09.2022, p. S1399-S1399.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - Primary results of the phase III KEYNOTE-412 study

T2 - Annual Meeting of the European-Society-for-Medical-Oncology (ESMO)

AU - Machiels, J-P.

AU - Tao, Y.

AU - Burtness, B.

AU - Tahara, M.

AU - Rischin, D.

AU - Alves, G. V.

AU - Lima, I. P. F.

AU - Hughes, B. G. M.

AU - Pointreau, Y.

AU - Aksoy, S.

AU - Laban, S.

AU - Greil, R.

AU - Burian, M.

AU - Hetnal, M.

AU - Licitra, L. F.

AU - Swaby, R.

AU - Zhang, Y.

AU - Gumuscu, B.

AU - Bidadi, B.

AU - Siu, L. L.

PY - 2022/9

Y1 - 2022/9

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=performanshacettepe&SrcAuth=WosAPI&KeyUT=WOS:000866211602439&DestLinkType=FullRecord&DestApp=WOS_CPL

U2 - 10.1016/j.annonc.2022.08.029

DO - 10.1016/j.annonc.2022.08.029

M3 - Meeting Abstract

SN - 0923-7534

VL - 33

SP - S1399-S1399

JO - Annals of Oncology

JF - Annals of Oncology

IS - 7

Y2 - 9 September 2022 through 13 September 2022

ER -

Primary results of the phase III KEYNOTE-412 study: Pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)

Access to Document

Other files and links

Cite this